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Opioid Use in Rhode Island – Review and Suggestions
By: Vanessa Kolb¹ Advisor: Dr. Bryan Dewsbury²
¹Psychology ²Biological Sciences
Background
• ~80% of heroin users report beginning use with 
prescription pain medications¹
• Since 2011, RI has reduced the number of 
prescription-related overdose deaths by 40%, but 
illegal drug overdose deaths have increased by 250%²
• Fentanyl is an inexpensive synthetic opioid said to be 
80 times more powerful than heroin. In 2011, 
Fentanyl had almost no presence in RI, but by 2015 it 
was implicated in 50% of overdose deaths²
• In 2015, ~250 Rhode Islanders died due to opioid 
overdoses³
Currently in Rhode Island
• RI requires all prescribers to consult the Prescription 
Drug Monitoring Program before any new opioid 
prescriptions, and once per year for long-term 
patients
• In 2015, Governor Raimondo’s Overdose Prevention 
and Intervention Task Force established a goal to 
reduce opioid-related deaths 33% by 2018. Their 
Strategic Action Plan includes:
• Improving prescribing practices
• Expanding the availability of Naloxone for 
overdoses
• Enhancing the quality and availability of 
Medication-assisted treatment (MAT)
• Increasing available support for those in recovery
• Launching a public education campaign²
• Additional programs include a 24/7 counselor hotline, 
making funding available for alternative chronic pain 
treatments, brochures with information about using 
Naloxone, seeking treatment and the dangers of 
Fentanyl, and the Anchor Recovery Community 
Center’s peer support services
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Extended-Release Injectable Naltrexone
• Opioid antagonist: blocks opioid receptors and 
prevents their effects – no potential for abuse
• Requires that patient has abstained from opioid use for 
7-10 days before beginning treatment 
• May be prescribed by anyone licensed to prescribe 
medications
• More expensive and more effective than methadone or 
buprenorphine, but when other healthcare costs are 
factored in, injectable Naltrexone is 49% less costly 
than methadone and comparable to buprenorphine 
treatment
• RI Department of Corrections is currently running a 
pilot program with the cooperation of the Office of 
Medicaid to determine the efficacy of monthly 
Naltrexone injections, started before release, in 
preventing relapse and reincarceration. Results are 
forthcoming⁴
Funding Available for Opioid-Related Programs
State Budget $4 million
To DOC for MAT programs $2.5 million
To DHHS for PDMP, Naloxone, Peer Recovery $740,000 
Matching Federal Medicaid $760,000 
Federal Grant: 21st Century Cures Act $2.1 million
Federal Grant: Medication-Assisted Treatment 
Prescription Drug Opioid Addiction Grant $1.9 million
Total $8 million
Supervised Injection Sites
• Controversial due to questionable legality, 
impression of condoning drug use, and refusal of 
neighborhoods to host the site
• Positive outcomes include reduced needle sharing, 
increased referral to treatment programs, and 
near zero rates of fatal overdoses for site users
• 63% of young adults in RI at risk for injecting 
opioids reported that they would be willing to use 
a supervised injection site; those who were at 
higher risk for overdosing had higher rates of 
willingness to utilize the site
• Cost-Benefit analyses of supervised injection sites 
generally focus on healthcare costs saved by 
preventing new cases of HIV and Hepatitis C
• Important variables: proportion of intravenous 
drug users (IDU) who are negative and positive for 
each health condition, rate of needle sharing, 
typical number of needle sharing partners, and 
the chances of infection from each shared needle 
use
• Not all of this data is currently available in RI. 
Additionally, the state’s only needle exchange 
program was defunded in 2016, making it difficult 
to accurately predict outcomes of a supervised 
injection site vs. multiple needle exchange sites
Considerations
• While strict monitoring of prescriptions is important, 
tapering or ‘cutting off’ a patient without an agreed-upon 
plan can lead to illicit drug use, increasing the likelihood 
of overdose⁵
• Because of its small population, RI is well-suited for 
programs that require strong communication and 
collaboration between agencies⁴
• The greatest number of resources are located in the 
Providence area, but this does not reflect the needs of 
many RI residents. Programs that require excessive daily 
travel may prove ineffective.
Suggestions
• Making injectable Naltrexone widely available for suitable 
candidates should be a priority. It is easily prescribed, has 
no abuse potential, and eliminates the need for daily 
visits to a clinic for MAT, which decreases the number of 
people who quit treatment
• Supervised injection sites may be helpful for reducing 
overdose deaths, but needle exchange programs should 
be made widely available first. The necessary data about 
IDUs and HIV/Hepatitis C rates can then be collected. 
Reduce patient burden to remain in MAT 
programs
Create multiple needle exchange sites
Make use of RI’s ability to easily collaborate
